Immatics Announces Second Quarter 2026 Financial Results and Business Update
Immatics reported Q2 revenue of $10.4 million, doubling from the prior year, while narrowing its net loss to $71.2 million. The company ended the quarter with $448.2 million in cash, funding operations into 2028, and confirmed that its SUPRAME Phase 3 trial remains on track with a streamlined final analysis now planned for H1 2027.
Key figures
- Revenue
- 10400000
- Net loss usd
- 71200000
- Ga expenses usd
- 15800000
- Rd expenses usd
- 71100000
- Cash position usd
- 448200000
- Anzu cel phase1b cor
- 56%
- Bla submission timing
- 2027
- Ima203cd8 phase1b orr
- 63%
- Suprame final analysis timing
- H1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.